Senseonics (NYSE:SENS) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Monday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Trading Down 1.7 %

SENS opened at $0.34 on Monday. The stock has a market cap of $178.32 million, a PE ratio of -2.40 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. Senseonics has a twelve month low of $0.32 and a twelve month high of $0.75. The company has a fifty day moving average of $0.38 and a 200-day moving average of $0.42.

Senseonics (NYSE:SENS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. On average, sell-side analysts predict that Senseonics will post -0.13 EPS for the current year.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. Vanguard Group Inc. increased its stake in Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after acquiring an additional 211,128 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Senseonics during the 1st quarter valued at about $162,000. 12.36% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.